493 related articles for article (PubMed ID: 24928921)
1. Fenofibrate vs pioglitazone: Comparative study of the anti-arthritic potencies of PPAR-alpha and PPAR-gamma agonists in rat adjuvant-induced arthritis.
Koufany M; Jouzeau JY; Moulin D
Biomed Mater Eng; 2014; 24(1 Suppl):81-8. PubMed ID: 24928921
[TBL] [Abstract][Full Text] [Related]
2. Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.
Koufany M; Moulin D; Bianchi A; Muresan M; Sebillaud S; Netter P; Weryha G; Jouzeau JY
Arthritis Res Ther; 2008; 10(1):R6. PubMed ID: 18199331
[TBL] [Abstract][Full Text] [Related]
3. The peroxisome proliferator-activated receptor γ agonist pioglitazone preserves bone microarchitecture in experimental arthritis by reducing the interleukin-17-dependent osteoclastogenic pathway.
Koufany M; Chappard D; Netter P; Bastien C; Weryha G; Jouzeau JY; Moulin D
Arthritis Rheum; 2013 Dec; 65(12):3084-95. PubMed ID: 23982996
[TBL] [Abstract][Full Text] [Related]
4. Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.
Samadfam R; Awori M; Bénardeau A; Bauss F; Sebokova E; Wright M; Smith SY
J Endocrinol; 2012 Feb; 212(2):179-86. PubMed ID: 22062085
[TBL] [Abstract][Full Text] [Related]
5. Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.
Oliveira AC; Bertollo CM; Rocha LT; Nascimento EB; Costa KA; Coelho MM
Eur J Pharmacol; 2007 Apr; 561(1-3):194-201. PubMed ID: 17343847
[TBL] [Abstract][Full Text] [Related]
6. Possible beneficial effect of peroxisome proliferator-activated receptor (PPAR)--α and γ agonist against a rat model of oral dyskinesia.
Grover S; Kumar P; Singh K; Vikram V; Budhiraja RD
Pharmacol Biochem Behav; 2013 Oct; 111():17-23. PubMed ID: 23948071
[TBL] [Abstract][Full Text] [Related]
7. Effects of pioglitazone and fenofibrate co-administration on bone biomechanics and histomorphometry in ovariectomized rats.
Smith SY; Samadfam R; Chouinard L; Awori M; Bénardeau A; Bauss F; Guldberg RE; Sebokova E; Wright MB
J Bone Miner Metab; 2015 Nov; 33(6):625-41. PubMed ID: 25534548
[TBL] [Abstract][Full Text] [Related]
8. Anti-arthritic and anti-inflammatory activity of combined pioglitazone and prednisolone on adjuvant-induced arthritis.
Suke SG; Negi H; Mediratta PK; Banerjee BD; Sharma KK
Eur J Pharmacol; 2013 Oct; 718(1-3):57-62. PubMed ID: 24075936
[TBL] [Abstract][Full Text] [Related]
9. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
Abd El-Haleim EA; Bahgat AK; Saleh S
Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis.
Okamoto H; Iwamoto T; Kotake S; Momohara S; Yamanaka H; Kamatani N
Clin Exp Rheumatol; 2005; 23(3):323-30. PubMed ID: 15971419
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate and pioglitazone do not ameliorate the altered vascular reactivity in aorta of isoproterenol-treated rats.
Fukuda LE; Davel AP; Verissimo-Filho S; Lopes LR; Cachofeiro V; Lahera V; Rossoni LV
J Cardiovasc Pharmacol; 2008 Nov; 52(5):413-21. PubMed ID: 19033820
[TBL] [Abstract][Full Text] [Related]
12. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
[TBL] [Abstract][Full Text] [Related]
13. Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.
Laurent D; Gounarides JS; Gao J; Boettcher BR
Diabetes Obes Metab; 2009 Jun; 11(6):632-6. PubMed ID: 19175377
[TBL] [Abstract][Full Text] [Related]
14. PPAR agonists stimulate adipogenesis at the expense of osteoblast differentiation while inhibiting osteoclast formation and activity.
Patel JJ; Butters OR; Arnett TR
Cell Biochem Funct; 2014 Jun; 32(4):368-77. PubMed ID: 24615887
[TBL] [Abstract][Full Text] [Related]
15. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
16. Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.
Ye P; Fang H; Zhou X; He YL; Liu YX
Chin Med Sci J; 2004 Dec; 19(4):243-7. PubMed ID: 15669179
[TBL] [Abstract][Full Text] [Related]
17. The impact of single and combined PPAR-α and PPAR-γ activation on the neurological outcomes following cerebral ischemia reperfusion.
Shehata AHF; Ahmed AF; Abdelrehim AB; Heeba GH
Life Sci; 2020 Jul; 252():117679. PubMed ID: 32325134
[TBL] [Abstract][Full Text] [Related]
18. Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.
Deehan R; Maerz-Weiss P; Catlett NL; Steiner G; Wong B; Wright MB; Blander G; Elliston KO; Ladd W; Bobadilla M; Mizrahi J; Haefliger C; Edgar A
PLoS One; 2012; 7(4):e35012. PubMed ID: 22514701
[TBL] [Abstract][Full Text] [Related]
19. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
20. Fenofibrate, a PPAR{alpha} agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy.
Castillero E; Nieto-Bona MP; Fernández-Galaz C; Martín AI; López-Menduiña M; Granado M; Villanúa MA; López-Calderón A
Am J Physiol Endocrinol Metab; 2011 May; 300(5):E790-9. PubMed ID: 21304067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
